Genta Inc. released the results from a pilot study on advanced melanoma incorporating the Company’s cancer drug Genasense(R) (oblimersen sodium). This study was featured earlier this week in a presentation at the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany, an international conference organized every year by a co-leader of the AGENDA trial, the European Association of Dermatologic Oncology (EADO).

Genasense, delivered for the first time in a high-dose, 1-hour intravenous (IV) format, was used along with the most common melanoma drug temozolomide (Temodar(R); Schering Plough, Inc.), and a paclitaxel suspension (Abraxane(R); Abraxis Bioscience, Inc.). Using a standard dose and schedule of Genasense, 500 mg over 24 hours for 7 days, showed good tolerability for 18 patients and was associated with clinical activity in prior results using this investigational combination of drugs.

Genasense, administered in this more aggressive schedule (1-hour IV twice a week for 4 weeks at 900 mg

...

Champions Biotechnology Inc. focuses on oncology drug developments and preclinical platforms and data to enhance and accelerate the value of those drugs. The company today announced an exclusive licensing agreement with Yale University and Southern Research Institute for the development of Bithionol for cancer treatment.

According to scientists from Yale and Southern Research, Bithionol, which is available for parasitic infections, shows activity against solid cancerous tumors and may be effective in treating melanoma, prostate, breast, lung and other cancers.

Per the agreement, Yale and Southern Research will receive an upfront payment, as well as milestone payments and royalties; Champions has exclusive rights for continued development of Bithionol for all oncology applications, and will use its predictive Biomerk Tumorgraft platform to determine optimal applications and efficient clinical development. If Champions is able to deliver results, the company will conduct human clinical trials.

“We are excited to work with Champions’ experienced scientific

...

TapImmune Inc. is a biotechnology company headquartered in Bellevue, Washington. They specialize in the development of immunotherapeutic vaccines for cancer and infectious diseases. Their core business focus is on emerging technologies based on cellular immunology and genetic understanding of the cause and potential novel treatments of disease.

TapImmune Inc.’s lead product is the TAP vaccine. It performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers. Therefore, the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In addition, the TAP molecule works as an adjuvant (accelerant) to enhance targeted vaccines against infectious diseases.

The Company is developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The expectation is that the global vaccine market will grow from $13 billion in 2007 to $21 billion

...

MannKind Pharma’s (MNKD) third quarter loss per share came in at 42 cents, better than the Zacks Consensus Estimate of 49 cents and loss of 67 cents reported in the year-ago period. The company does not have any revenue stream at present -- its lead product, Afresa (inhaled insulin for the treatment of type I and type II diabetes) is currently under US Food and Drug Administration (FDA) review. MannKind filed a New Drug Application (NDA) for Afresa with the FDA in March 2009, which was subsequently accepted in May 2009. The company has been assigned a Prescription Drug User Fee Act (PDUFA) date of January 16, 2010. Operating expenses for the third quarter declined 38% to $42.8 million, primarily due to a huge reduction in R&D expenses. Reduced costs associated with the clinical development of Afresa along with a decline in manufacturing costs brought down ...

In the great state of Tennessee, there is a company that is on the cutting edge of cancer research and has taken their technology worldwide in an attempt to help cure the disease. The company is Provectus Pharmaceuticals and if they achieve continued success, they may soon be a well known name.

Provectus Pharmaceuticals is a development-stage oncology and dermatology biopharmaceutical company which uses the agent PV-10 as a therapeutic agent for a broad spectrum of cancers. Currently, PV-10 is available for select cancer patients in the U.S. but the program was initiated in Australia in June of 2009 and has excelled across the globe.

In the U.S., the PV-10 program commenced at St. Luke’s Hospital and Health Network in Bethlehem, PA under the watchful eye of the renowned Dr. Sanjiv Agarwaia who served as the Principal Investigator at that site for the Phase 2 Melanoma Trial. The U.S.

...

On a Monday afternoon, Enzon Pharmaceuticals made an announcement that FDA Oncologic Drug Advisory Committee has voted in the favor of and has approved the use of Pegintron as a treatment in addition to surgery in patients with metastatic melanoma. The news of FDA approval has boosted Enzon Pharmaceuticals and even the shares of the company have moved upwards on the market charts. The drug Pegintron is currently being manufactured, marketed and developed by Schering-Plough. The product is currently being used for the treatment of chronic hepatitis C in patients over 18 years of age.

Enzon Pharmaceuticals is a biopharmaceutical company that is dedicated to the development and commercialization of important life saving for patients who are suffering from cancer and other life threatening diseases. The FDA has approved that

...

Provectus Pharmaceuticals Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of their drug – PV-10 – for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. The same drug is currently undergoing Phase 2 study for metastatic melanoma.

The primary objective of the open-label study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with liver cancer. Additional objectives are to assess the distribution and retention of PV-10 in the injected lesion, tumor response and viability, and plasma pharmacokinetics of the drug following intralesional injection.

The CEO of Provectus, Dr. Craig Dees, PhD, spoke about the Phase 1 trial, “We hope to demonstrate that PV-10, which has shown excellent selectivity for melanoma, will be a viable therapeutic for liver cancer and cancers metastatic to the liver.”

The

...

Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

...

Biopharma Vical (NASDAQ:VICL) has risen to its highest share price in a year — and with rumors of a buyout offer, it shows no sign of stopping.

The share price for Vical Incorporated (NASDAQ:VICL) jumped over 15% earlier this month on the news that a U.S. patent had been granted for its Vaxfectin-formulated DNA influenza vaccines.

Now with the addition of rumors of a buyout offer from generic drug giant Teva Pharmaceuticals Ltd. (NASDAQ:TEVA), this company is rapidly becoming a superstar!

We saw the potential for Vical here at TFN. Readers that acted on our FREE recommendation of VICL in our Aug. 20 Report, The Top 6 Swine Flu Vaccine Stocks Under $20 are sitting on gains of around 46%!

The rumors could prove true

In early August, Vical announced an agreement with a subsidiary of Teva (Abic Marketing Limited) allowing Abic exclusive marketing rights for the company’s drug Allovectin-7

...

bSummary/bbrbr Scancell is developing a product platform that uniquely stimulates the immune system to treat disease. The corporate strategy is simple – spend the next two years conducting “proof of concept” studies in melanoma patients, run animal trials in parallel targeting angiogenesis to confirm it as a platform technology, and then sell off the technology to the highest bidder. To use a baseball analogy, Scancell is heading to the plate and swinging for the fences. With a differentiated technology and a focused plan, we think this Company has what it takes to circle the bases. pBKey points:/BBRBRul pli type=squarebA high risk, high reward proposition/bbr As history has shown, the path to market for therapeutic cancer vaccines is not going to be an easy one. Many bodies litter the road and the science is still very much evolving, but to the winners go the spoils. Using a conservative set of assumptions and a heavily discounted valuation methodology, we still derived a base case value for Scancell ...